Iasophyr

Nitric Oxide, the active ingredient in Iasophyr, is a medical gas presented as an inhalation gas for inhalation use. It is employed to manage pulmonary hypertension and neonatal respiratory distress syndrome by dilating the pulmonary vasculature in affected patients.

GNH USA supplies Iasophyr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, and specialty clinics worldwide. The product complies with European Union regulatory standards and is distributed under strict quality‑assured conditions. GNH USA's global network ensures reliable logistics and regulatory support for cross‑border procurement.

Iasophyr is used as an inhaled pulmonary vasodilator to treat conditions characterized by elevated pulmonary vascular resistance.

Pulmonary hypertension: reduces pulmonary arterial pressure and improves exercise capacity. Neonatal respiratory distress syndrome: improves oxygenation by decreasing pulmonary vascular tone in newborns.

Iasophyr may be associated with a range of adverse reactions following inhalation.

Common Side Effects: - Headache: mild to moderate headache reported during therapy. - Flushing: transient skin flushing. - Hypotension: mild systemic blood pressure drop. - Methemoglobinemia: dose‑related increase in methemoglobin levels. - Bronchospasm: transient narrowing of airways in susceptible patients.

Serious or Rare Side Effects: - Severe hypotension: marked drop in systemic blood pressure requiring intervention. - Rebound pulmonary hypertension: rapid increase in pulmonary pressure after abrupt discontinuation. - Significant methemoglobinemia: levels >10% causing cyanosis. - Bleeding complications: rare hemorrhagic events in coagulopathic patients.

When prescribing Iasophyr, clinicians should observe several safety considerations. - Patient selection: confirm diagnosis of pulmonary hypertension or neonatal distress before use. - Monitoring: regularly assess pulmonary artery pressure and methemoglobin levels during therapy. - Dose titration: adjust inhaled concentration based on clinical response and tolerance. - Contraindications: avoid in patients with known hypersensitivity to nitric oxide or severe left‑heart disease. - Store at ambient temperature: keep cylinder in a cool, dry place, protected from direct sunlight and secure from damage.

Iasophyr can interact with other agents that affect vascular tone or hemoglobin metabolism.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): additive pulmonary vasodilation may cause severe hypotension. - Nitroglycerin or other nitric oxide donors: risk of excessive systemic vasodilation. - Methylene blue: impairs nitric oxide signaling and may reduce efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., heparin): increased risk of bleeding when combined with severe hypotension. - Inhaled anesthetics (e.g., sevoflurane): may potentiate vasodilatory effects. - Drugs causing oxidative stress (e.g., high‑dose vitamin C): may influence methemoglobin formation.